Royale Energy, Inc.(NASDAQ:ROYL) shares soared 39.08% to $4.47 in the morning hour. The company’s Co-CEO Stephen Hosmer spoke to delegates at the Alaska Oil and Gas Congress in Anchorage last week. While sharing the stage with CEO of Great Bear Petroleum Operating LLC, Ed Duncan discussed the results of their initial test wells (Alcor #1 and Merak #1) in which they cored portions of the Shublik, HRZ/GRZ, and Kingak shales, the source rock for Alaska's Prudhoe Bay oil field.
Will ROYL Continue To Move Higher? Find Out Here
Tempur-Pedic International Inc.(NYSE:TPX) shares jumped 15.76% to $30.82 after Tempur-Pedic and Sealy Corp announced that they have signed a definitive agreement to create a $2.7 billion global bedding provider. The transaction has been approved by the Boards of Directors of both companies. Tempur-Pedic will acquire all of the outstanding common stock of Sealy for $2.20 per share, representing a premium of approximately 23% to Sealy's 30-day average closing price on September 26, 2012.The transaction is expected to close during the first half of 2013.
OCZ Technology Group Inc.(NASDAQ:OCZ) stock increased 7.21% to $3.57. The company last week said that it has changed it top management but efforts to win back investor confidence is expected to take more time as the company, which has not made a profit for almost a year, has to first fix a supply chain problem.
How Should Investors Trade With Today’s recovery? Find Out Here
The company’s Chief Executive Ryan Petersen has resigned, a month after it announced the retirement of Chief Financial Officer Arthur Knapp.
Thor Industries, Inc.(NYSE:THO) stock climbed 7.44% to $36.97 after the company posted fourth quarter net income of $44.4 million or $0.84 per share from $37.0 million or $0.66 per share in the same period last year. Consolidated sales were $888.2 million, up 15% from $770.5 million in the same period last year. Analysts expected the company to earn $0.77 per share on revenues of $886.84 million.
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) shares gained 6.20% to $10.08 after the company announced positive proof-of-concept results with ACH-3102, a second-generation pan-genotypic NS5A inhibitor being developed for the treatment of chronic hepatitis C viral infections (HCV). Administration of a single-dose of ACH-3102 to genotype 1a HCV-infected subjects resulted in a mean maximum 3.74 log10 reduction in HCV RNA (range 2.9 - 4.6 log10). Significant reductions in HCV RNA were achieved in subjects with resistant variants at baseline, including L31M and Y93C variants.